No Data
Linuo Pharmaceuticals: 2024 Annual Report Summary
Linuo Pharmacopoeia: 2024 Annual Report
Linuo Pharmacopoeia: Report for the first quarter of 2025
Lianuo Pharmaceutical (301188.SZ): Net income of 40.52 million yuan in the first quarter, a year-on-year increase of 63.36%.
On April 24, Gelonghui reported that Linuo Pharmaceutical (301188.SZ) announced its first quarter report, with revenue of 0.276 billion yuan, a year-on-year increase of 3.38%. The net income attributable to shareholders of the listed company was 40.52 million yuan, a year-on-year increase of 63.36%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 37.075 million yuan, a year-on-year increase of 67.51%.
Linuo Pharmaceutical (301188.SZ): A total of 0.5% of shares have been repurchased.
On April 1st, Gelonghui reported that Linuo Pharmaceuticals (301188.SZ) announced that as of March 31, 2025, the company has cumulatively repurchased a total of 1,167,500 shares using its own funds and special loan funds for Share Buyback through a dedicated Securities Account via centralized bidding, accounting for 0.50% of the company's current total share capital. The highest Fill Price for the repurchased shares was 16.67 yuan/share, and the lowest Fill Price was 15.66 yuan/share, with a total transaction amount of 18,751,179 yuan (excluding transaction fees). The company's Share Buyback progress complies with relevant laws and regulations and meets the established.
Express News | Shandong Linuo Says to Set up Pharmaceutical Packaging Products Jv With Santisa Laboratório Farmacêutico in Brazil
There Are Reasons To Feel Uneasy About Shandong Linuo Technical GlassLtd's (SZSE:301188) Returns On Capital
